Updated NCCN guidelines for multiple myeloma add dedicated recommendations for MRD testing, prefer tests that can detect one cancer cell among 1 million cells and expand when testing should occur.
|Videos|October 21, 2016
Moving Mountains for Multiple Myeloma: The Machu Picchu Climb
The Moving Mountains for Multiple Myeloma (MM4MM) team completed another amazing hike to raise money for the Multiple Myeloma Research Foundation (MMRF).
Advertisement
The Moving Mountains for Multiple Myeloma (MM4MM) team completed another amazing hike to raise money for the Multiple Myeloma Research Foundation (MMRF).
The Moving Mountains team consists of patients, doctors and loved ones who climbed Mount Kilimanjaro in January 2016 to raise money for multiple myeloma awareness and research, benefitting the MMRF. For more information, visit
Advertisement
Related to this article
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.
Advertisement
Advertisement